Archive for March 2018

Marc Moss, MD

Marc Moss

Marc Moss is the Roger S. Mitchell Professor of Medicine and Vice Chair of Clinical Research for the Department of Medicine at the University of Colorado School of Medicine. For more than 17 years, Dr. Moss has received continuous NIH funding as a principal investigator, and his research has been published in high impact journals.…

Read More

Kevin Kinsella

Kevin Kinsella

Kevin Kinsella has been investing in early-stage technology companies for over thirty years, through Avalon Ventures, a venture capital fund he founded. These companies have been responsible for bringing to market several multibillion-dollar drugs for cancer, rheumatoid arthritis, cystic fibrosis, the Apple iPhone touch-screen, Big Data software to discover oil and gas, cloud computing, AI…

Read More

Tara Butler, MD

Tara Butler

Tara Butler came to Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several Ascension Ventures portfolio companies, including Apama Medical, Augmenix, CHF Solutions, Confluent…

Read More

Irina Petrache, MD

Irina Petrache

Irina Petrache is Professor of Medicine at National Jewish Health and University of Colorado, Denver, CO. Dr. Petrache received her medical degree from the “Carol Davila” University of Medicine and Pharmacy in Bucharest, Romania and received postgraduate training in Internal Medicine at Saint Luke’s/St Vincent Medical Center/Case Western Reserve University in Cleveland, OH; and in…

Read More

Jason Chien, MD

Jason Chien

Jason Chien currently serves as the Gilead global lead for respiratory viruses. In this role, Jason helps Gilead define the overall commercial and development strategy for addressing the respiratory virus related unmet need in adults and children. Prior to joining Gilead in 2011, Jason was on faculty at the University of Washington and at Fred…

Read More

Fred Van Goor, PhD

Fred Van Goor

Dr. Van Goor is a research and development leader with expertise in protein folding and ion channel function as applied to discovery and development of breakthrough therapeutics for cystic fibrosis. He has a strong background in applying biological approaches (assay development, screening, molecular biology, and pharmacology) to drug discovery and advancing successful compounds from lab…

Read More

James Donohue, MD

James Donohue

Dr. Donohue’s research interests include new therapeutics in chronic obstructive pulmonary disease, alpha-1 antitrypsin deficiencies and asthma. He has previously served on the editorial advisory boards of numerous journals including COPD: Journal of Chronic Obstructive Pulmonary Disease, Medscape Pulmonary Medicine and Current Respiratory Medical Review, and is an ad hoc reviewer for many journals, including…

Read More

Colin Reisner, MD

Colin Reisner

Dr. Colin Reisner is Senior Vice President and Head of Late Stage RIA (Respiratory, Inflammation & Autoimmunity), BioPharmaceuticals R&D, AstraZeneca. He is an innovative leader with more than 20 years of international experience at top-tier companies, having previously workred at Boehringer Ingelheim, GSK and Novartis. Colin has extensive experience in both large and small companies,…

Read More

Timothy Shannon, MD

Tim Shannon

Timothy Shannon, MD, is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at IDEAYA, NextCure and Vivace. Prior successful companies include Civitas Theraputics (acquired by Acorda), Novira Therapeutics (acquired by Johnson & Johnson) and…

Read More

Bernard Coulie, MD, PhD

Bernard Coulie

Pliant CEO Bernard Coulie, MD, PhD brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the…

Read More